ClinicalTrials.gg
CompletedNCT04888169SMARTUpdated Oct 30, 2026Results posted

Studying the Modification of Attention Bias Remotely After Trauma

An interventional study of SMART Mobile App - Attention Bias Modification and SMART Mobile App - Attention Control Training in Post Traumatic Stress Disorder, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 30, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
872
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Stress Disorders, Post-Traumatic by University of California, San Francisco — 2 open to participants now, 2 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of California, San Francisco.

Enrollment
2nd of 14
872 · median 74
Started
2023
with 1 other
No phase
9 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies in Stress Disorders, Post-Traumatic by University of California, San Francisco, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 with no phase, and was the 15th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

2 of the 17 studies in Stress Disorders, Post-Traumatic by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Stress Disorders, Post-Traumatic by University of California, San Francisco, or all of them as a file.
02

Study summary

The investigators will complete an entirely remote randomized controlled trial (RCT) comparing 14 sessions of attention bias modification (ABM), attention control training (ACT), placebo neutral attention training, and a final control condition with daily questions in 1,897 individuals with clinically significant Post-traumatic Stress Symptoms (PTSS) (defined as PCL-5 score ≥ 33). To assess effects of the training and control conditions, the investigators will administer tests of threat-related attention bias and variability, and self-report assessments of PTSS, depression, anxiety, and perceived stress at baseline, after one and two weeks of training, and at eight-week follow up. The investigators plan to screen and confirm interest from over 3,000 eligible participants over a period of 24 months to enroll and randomize 1,897 participants with the end goal of 1,232 completers (176 per condition).

03

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • Attention bias
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 65 years
  • Score at or above 33 on the PCL-5,
  • Able and willing to perform daily smartphone training for two weeks
  • Fluent English comprehension.
  • Owns Android or iPhone smartphone

Exclusion criteria

Exclusion Criteria:

  • Does not have Android or iPhone Operating System (iOS) smartphone running sufficient software (i.e. at least iOS 10.1), and is not willing to update
  • Active suicidality.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
872 participants (actual)

Study arms

  • Experimental
    Attention Bias Modification - Word Stimuli

    Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.

    Device: SMART Mobile App - Attention Bias Modification

  • Active comparator
    Attention Bias Modification - Face Stimuli

    Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.

    Device: SMART Mobile App - Attention Bias Modification

  • Experimental
    Attention Control Training - Word Stimuli

    Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (i.e. one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.

    Device: SMART Mobile App - Attention Control Training

  • Active comparator
    Attention Control Training - Face Stimuli

    Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.

    Device: SMART Mobile App - Attention Control Training

  • Placebo comparator
    Placebo Attention Training - Word Stimuli

    Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral words) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.

    Device: SMART Mobile App - Placebo Training

  • Placebo comparator
    Placebo Attention Training - Face Stimuli

    Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral faces) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.

    Device: SMART Mobile App - Placebo Training

  • Sham comparator
    Control - Questions

    The Control - Questions condition will only deliver a set of daily questions for participants to answer. Questions will ask about a variety of psychological factors such as mood, stress experiences, daily exercise and more.

    Device: SMART Mobile App - Control

Interventions

  • DeviceSMART Mobile App - Attention Bias Modification

    ABM involves placing the probe behind the neutral stimulus on 100% of the trials.

  • DeviceSMART Mobile App - Attention Control Training

    ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.

  • DeviceSMART Mobile App - Placebo Training

    Placebo training only includes neutral stimuli.

  • DeviceSMART Mobile App - Control

    Participants will only answer questions.

06

What researchers measure

Primary outcomes

  1. Change in PTSD Checklist-5 (PCL) Score (Before/After Training)

    Reported are the changes in the PTSD Checklist for the DSM-5 (PCL-5) scores between baseline (Day 1) and post-training (Day 28) in each group. The PCL-5 assesses the presence and severity of 20 different symptoms in posttraumatic stress disorder (PTSD). Each of the 20 items is scored on a severity range of 0 ("Not at All") to 4 ("Extremely"), for a final score range of 0 - 80. A score of 33 and above is indicative of clinically significant PTSD symptoms. Higher scores indicate worse PTSD symptom severity. A 10 point change (up or down) is considered a clinically significant change in PTSD symptoms.

    Time frame: Baseline, 4 weeks

  2. Change in PTSD Checklist-5 (PCL) Score (Follow-up)

    Reported are the changes in the PTSD Checklist for the DSM-5 (PCL-5) scores between post-training (Day 28) and follow-up (Day 56) in each group. The PCL-5 assesses the presence and severity of 20 different symptoms in posttraumatic stress disorder (PTSD). Each of the 20 items is scored on a severity range of 0 ("Not at All") to 4 ("Extremely"), for a final score range of 0 - 80. A score of 33 and above is indicative of clinically significant PTSD symptoms. Higher scores indicate worse PTSD symptom severity. A 10 point change (up or down) is considered a clinically significant change in PTSD symptoms.

    Time frame: 4 weeks, 8 Weeks

07

Results

Posted Oct 30, 2026

Participant flow

Baseline - Post-Training
Participant flow — Baseline - Post-Training
MilestoneAttention Bias Modification - Word StimuliAttention Bias Modification - Face StimuliAttention Control Training - Word StimuliAttention Control Training - Face StimuliPlacebo Attention Training - Word StimuliPlacebo Attention Training - Face StimuliControl - Questions
Started123126124124127125123
Completed71717285788287
Not completed52555239494336
Post-Training - Follow-Up
Participant flow — Post-Training - Follow-Up
MilestoneAttention Bias Modification - Word StimuliAttention Bias Modification - Face StimuliAttention Control Training - Word StimuliAttention Control Training - Face StimuliPlacebo Attention Training - Word StimuliPlacebo Attention Training - Face StimuliControl - Questions
Started71717285788287
Completed67666479736572
Not completed458651715

Outcome measures

PrimaryChange in PTSD Checklist-5 (PCL) Score (Before/After Training)

Reported are the changes in the PTSD Checklist for the DSM-5 (PCL-5) scores between baseline (Day 1) and post-training (Day 28) in each group. The PCL-5 assesses the presence and severity of 20 different symptoms in posttraumatic stress disorder (PTSD). Each of the 20 items is scored on a severity range of 0 ("Not at All") to 4 ("Extremely"), for a final score range of 0 - 80. A score of 33 and above is indicative of clinically significant PTSD symptoms. Higher scores indicate worse PTSD symptom severity. A 10 point change (up or down) is considered a clinically significant change in PTSD symptoms.

Time frame:
Baseline, 4 weeks
Reported as:
Mean · Scores on a scale
Change in PTSD Checklist-5 (PCL) Score (Before/After Training)
Scores on a scaleAttention Bias Modification - Word StimuliAttention Bias Modification - Face StimuliAttention Control Training - Word StimuliAttention Control Training - Face StimuliPlacebo Attention Training - Word StimuliPlacebo Attention Training - Face StimuliControl - Questions
Change in PTSD Checklist-5 (PCL) Score (Before/After Training)-4.54 ± 15.06-5.37 ± 14.42-4.65 ± 15.1-6.73 ± 11.71-3.81 ± 12.97-4.79 ± 12.79-2.66 ± 12.99
PrimaryChange in PTSD Checklist-5 (PCL) Score (Follow-up)

Reported are the changes in the PTSD Checklist for the DSM-5 (PCL-5) scores between post-training (Day 28) and follow-up (Day 56) in each group. The PCL-5 assesses the presence and severity of 20 different symptoms in posttraumatic stress disorder (PTSD). Each of the 20 items is scored on a severity range of 0 ("Not at All") to 4 ("Extremely"), for a final score range of 0 - 80. A score of 33 and above is indicative of clinically significant PTSD symptoms. Higher scores indicate worse PTSD symptom severity. A 10 point change (up or down) is considered a clinically significant change in PTSD symptoms.

Time frame:
4 weeks, 8 Weeks
Reported as:
Mean · Scores on a scale
Change in PTSD Checklist-5 (PCL) Score (Follow-up)
Scores on a scaleAttention Bias Modification - Word StimuliAttention Bias Modification - Face StimuliAttention Control Training - Word StimuliAttention Control Training - Face StimuliPlacebo Attention Training - Word StimuliPlacebo Attention Training - Face StimuliControl - Questions
Change in PTSD Checklist-5 (PCL) Score (Follow-up)-4.42 ± 15.51-4.74 ± 19.32-6.14 ± 15.8-5.04 ± 12.61-7.27 ± 16.5-4.72 ± 12.77-8.65 ± 17.22

Adverse events

Collected over From baseline assessment until the end of follow-up, approximately 8 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Attention Bias Modification - Word Stimuli0/123 (0%)0/123 (0%)0/123 (0%)
Attention Bias Modification - Face Stimuli0/126 (0%)0/126 (0%)0/126 (0%)
Attention Control Training - Word Stimuli0/124 (0%)0/124 (0%)0/124 (0%)
Attention Control Training - Face Stimuli0/124 (0%)0/124 (0%)0/124 (0%)
Placebo Attention Training - Word Stimuli0/127 (0%)0/127 (0%)0/127 (0%)
Placebo Attention Training - Face Stimuli0/125 (0%)0/125 (0%)0/125 (0%)
Control - Questions0/123 (0%)0/123 (0%)0/123 (0%)

Baseline characteristics

Baseline measures (i.e., age, gender, race/ethnicity) were collected for all participants who completed screening surveys.

Age, Continuous
Age, Continuous(Years)Attention Bias Modification - Word StimuliAttention Bias Modification - Face StimuliAttention Control Training - Word StimuliAttention Control Training - Face StimuliPlacebo Attention Training - Word StimuliPlacebo Attention Training - Face StimuliControl - QuestionsTotal
Mean32 ± 1033 ± 1131 ± 931 ± 930 ± 832 ± 932 ± 832 ± 9
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Attention Bias Modification - Word StimuliAttention Bias Modification - Face StimuliAttention Control Training - Word StimuliAttention Control Training - Face StimuliPlacebo Attention Training - Word StimuliPlacebo Attention Training - Face StimuliControl - QuestionsTotal
Man35334247434640286
Woman81877773757377543
Other11111229
Missing654384434
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Attention Bias Modification - Word StimuliAttention Bias Modification - Face StimuliAttention Control Training - Word StimuliAttention Control Training - Face StimuliPlacebo Attention Training - Word StimuliPlacebo Attention Training - Face StimuliControl - QuestionsTotal
Race/Ethnicity — American Indian / Alaskan01020025
Race/Ethnicity — Asian482781737
Race/Ethnicity — Black / African American26313129313829215
Race/Ethnicity — Hispanic / Latinx223332621
Race/Ethnicity — Middle Eastern / North African11110015
Race/Ethnicity — Native Hawaiian / Pacific Islander00010012
Race/Ethnicity — White / Caucasian54495057565847371
Race/Ethnicity — Missing36343724292630216
08

Study locations

1 site
  • Tommy Atwater
    San Francisco, California 94143, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jun 2025, 26 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion. A results delay was requested in Jun 2026.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 26 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2021
First posted
May 17, 2021
StartActual
Apr 20, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results delay requested
Jun 26, 2026
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Enrollment
1314→872
Oct 30, 2026
Primary outcomes
2 description edited
What changed in the outcomes
  • DescriptionChange in PTSD Checklist-5 (PCL) Score (Before/After Training): how it is measured was reworded
  • DescriptionChange in PTSD Checklist-5 (PCL) Score (Follow-up): how it is measured was reworded
Oct 30, 2026
Documents
Show all 1 update
  1. Oct 30, 2026
    Results posted
    Enrollment 1314→872
    Primary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionChange in PTSD Checklist-5 (PCL) Score (Before/After Training): how it is measured was reworded
    • DescriptionChange in PTSD Checklist-5 (PCL) Score (Follow-up): how it is measured was reworded
    + 3 other changes: verification date, registry dates and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04888169
Collaborators
San Francisco Veterans Affairs Medical Center
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Apr 20, 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Joshua Woolley, MD, PhD
principal investigator · UCSF, SFVAMC
Joaquin Anguera, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion